Grant ID RP240401
Awarded On February 21, 2024
Title Lead Optimization, Target Engagement and Efficacy Studies of Locally Bioavailable COX-2 inhibitors for Preventing Colon Cancer Progression in FAP Children
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Cancer in Children and Adolescents
Institution/Organization University of Houston
Principal Investigator/Program Director Ming Hu
Cancer Sites Childhood and Adolescent, Colorectal
Contracted Amount $1,400,000*

*Pending contract negotiation

Lay Summary

Familial adenomatous polyposis (FAP) is a devastating rare genetic disorder with no effective drug; all patients develop cancer unless the colon is surgically removed at an early age. Celecoxib, an FDA-approved selective COX-2 (cyclooxygenase 2) inhibitor, was once approved for the treatment of FAP. Unfortunately, this indication was withdrawn because chronic use of celecoxib, which is needed to inhibit polyp growth in patients with FAP, causes rare but serious cardiovascular toxicities, including death. The problem is, therefore, not the lack of a validated drug target, but identifying drugs to treat FAP patients without toxicity. To overcome this problem, we propose the development of loca...

Read More